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Abstract
Background: The hematopoietic protein Granulocyte-colony stimulating factor (G-CSF) has neuroprotective and -
regenerative properties. The G-CSF receptor is expressed by motoneurons, and G-CSF protects cultured motoneuronal cells
from apoptosis. It therefore appears as an attractive and feasible drug candidate for the treatment of amyotrophic lateral
sclerosis (ALS). The current pilot study was performed to determine whether treatment with G-CSF in ALS patients is
feasible.
Methods: Ten patients with definite ALS were entered into a double-blind, placebo-controlled, randomized trial. Patients
received either 10 mg/kg BW G-CSF or placebo subcutaneously for the first 10 days and from day 20 to 25 of the study.
Clinical outcome was assessed by changes in the ALS functional rating scale (ALSFRS), a comprehensive neuropsychological
test battery, and by examining hand activities of daily living over the course of the study (100 days). The total number of
adverse events (AE) and treatment-related AEs, discontinuation due to treatment-related AEs, laboratory parameters
including leukocyte, erythrocyte, and platelet count, as well as vital signs were examined as safety endpoints. Further-
more, we explored potential effects of G-CSF on structural cerebral abnormalities on the basis of voxel-wise statistics of
Diffusion Tensor Imaging (DTI), brain volumetry, and voxel-based morphometry.
Results: Treatment was well-tolerated. No significant differences were found between groups in clinical tests and brain
volumetry from baseline to day 100. However, DTI analysis revealed significant reductions of fractional anisotropy (FA)
encompassing diffuse areas of the brain when patients were compared to controls. On longitudinal analysis, the placebo
group showed significant greater and more widespread decline in FA than the ALS patients treated with G-CSF.
Conclusions: Subcutaneous G-CSF treatment in ALS patients appears as feasible approach. Although exploratory analysis of
clinical data showed no significant effect, DTI measurements suggest that the widespread and progressive microstructural
neural damage in ALS can be modulated by G-CSF treatment. These findings may carry significant implications for further
clinical trials on ALS using growth factors.
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Amyotrophic lateral sclerosis (ALS) is a devastating and
incurable neurodegenerative disease with progressive loss of motor
neurons. It is characterized by motor weakness and muscle wasting
finally leading to death due to respiratory failure within 2–5 years
after diagnosis [1]. A causal treatment for ALS is currently not
available. The only approved pharmacological treatment oppor-
tunity is a continuous treatment with the NMDA antagonist
riluzole. Riluzole prolongs life by 2–3 months, but an improve-
ment in neurological function is barely noticeable [2]. Therefore
treatment alternatives are urgently needed. A number of different
drugs were tested in clinical trials but none of them proofed to be
effective. The failures have mainly been ascribed to the inability of
candidate drugs to cross the blood-brain barrier (BBB), to
problems of insufficient dosing or to intolerable side effects [3,4].
Recent studies have uncovered the neuroprotective and
regenerative properties of the haematopoietic protein granulo-
cyte-colony stimulating factor (G-CSF) [5,6]. A number of
mechanisms of action in the CNS have been identified, the most
relevant relating to neuroprotection, neuroplasticity, stem cell
proliferation and differentiation. Thus, G-CSF could be a
promising therapeutic candidate for the treatment of neurode-
generative diseases. Given that the exact disease-causing mecha-
nism of ALS is still unknown, a general trophic support to
motoneurons, e.g. by growth factors such as G-CSF, could be a
rational approach. G-CSF crosses the intact BBB, thus allowing an
efficient peripheral delivery [6]. Moreover, G-CSF is in clinical
routine for the treatment of haematological disorders for more
than a decade and its pharmacological behavior and safety profile
are well understood.
The purpose of this pilot study was to assess whether G-CSF
treatment in ALS patients is feasible, and to explore potential
subclinical effects of G-CSF on structural cerebral abnormalities
by using a combination of voxel-based morphometry (VBM) and
whole-brain, voxel-based diffusion tensor imaging (DTI) analysis.
Methods
Participants and Procedures
Ten patients (median age 58 years; range 45–71 years; 6 men, 4
women) with definite ALS based on revised El Escorial criteria
were recruited for this double-blind, placebo-controlled and
randomized study [7]. The CONSORT flowchart is shown as
Figure 1. The here reported study, conducted according to ICH
GCP guidelines, was originally planned as a larger arm in a
registered recovery trial (ClinicalTrials.gov NCT00298597), but
due to problems in patient recruitment was conducted and
reported independently with a smaller number of patients. A
group of 32 healthy subjects (17 women, median age 54.1 years,
range 46 to 64 years) served as a control group for the cross-
sectional image analyses. Patients taking riluzole were included if
they were on a stable dose for at least 30 days before enrolment
(for further details on patients, see Table 1). After enrolment,
patients were randomly assigned to subcutanteous injections of G-
CSF or saline solution (10 mg/KG/day G-CSF or 0.1 mL/KG/
day placebo) during the first 10 days and from day 20 to 25 of the
study. The study drug was given in a double-blind way. Study
Figure 1. Consort Flowchart.
doi:10.1371/journal.pone.0017770.g001
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provided by the pharmacy of the University of Mainz. Filgrastim
(recombinant human G-CSF produced in E. coli, solubilised in a
buffer containing 10 mM acetic acid, 5% (m/v) sorbitol, 0.004%
Tween 80, ph adjusted to 4.0 with NAOH), or saline as placebo
were filled in identical-looking glass vials to ensure blinding. Vital
signs and laboratory parameters were determined repeatedly
throughout the course of the study.
Each patient was physically examined and a questionnaire for
the ALS functional rating scale (ALSFRS) was used to assess
disease severity [8]. To assess motor hand functions and cognitive
ability, the Jebsen Taylor Test (JTT) [9] and a comprehensive
neuropsychological test battery were conducted, respectively. An
experienced clinical neuropsychologist, who was unaware of the
allocation of the patients, conducted the neuropsychological tests.
Performances in five major areas of cognitive functioning were
evaluated. Cognitive domains and their particular tests are listed in
Table 2. The same test was not included in more than one
cognitive domain score. Concerning the Rey Osterrieth Complex
Figure Test, we also calculated the relative difference between
both test results since results of delayed recall performance can be
influenced by an impairment of initial copying. Due to the small
number of subjects, we additionally compared mean results of
each neuropsychological test with standardized normal values,
adjusted for age, sex, and educational level (see Table 2 for
baseline results). Differences were expressed semi quantitatively as
normal, close below average, or far below average, respectively. A
detailed description of each test can be found in Lezak et al. [10].
Additionally, safety endpoints were examined, that is, the total
number of adverse events (AEs), the number of treatment-related
AEs, and discontinuation due to treatment-related AEs. Secondly,
laboratory parameters including leukocyte, erythrocyte, and
platelet count, and vital signs (body temperature, blood pressure,
heart rate) were assessed.
Image acquisition and analysis
Image data were obtained on a 3.0 T system with a high
resolution structural T1-weighted 3D turbo-field-echo sequence
(reconstructed after zero filling to 51264106320 cubic voxels,
edge length 0.5 mm), as well as T2-weighted, and FLAIR imaging.
For DTI we employed echo planar imaging (EPI) with 20 diffusion
directions (36 slices, thickness 3.6 mm, matrix 1286128, inplane
resolution 1.861.8 mm).
MRI examinations of the ALS patients were performed at Day
0 and Day 100 of the study.
Diffusion tensor and FA (fractional anisotropy) field maps were
calculated from spatially normalised images. The method was
described in detail previously [11]. In brief, after correction for
eddy currents with an in-house software, the EPI images were
spatially normalized to the Montreal Neurological Institute (MNI)
coordinate system following an optimized procedure. The
diffusion tensor and FA field maps of all participants were
calculated from the spatially normalized images. In a second step,
all FA images were normalized to an FA template image also
corresponding to the MNI coordinate space. Fiber direction maps
were calculated on the basis of the largest eigenvector.
Patterns of cerebral atrophy were assessed using the automated
and unbiased technique of VBM. An optimized method of VBM
was applied using both customized templates and prior probability
maps, implemented using SPM5. The processing steps were
performed as previously described [12]. Briefly, all images were
normalized to a customized template and segmented by the
unified segmentation procedure in SPM5 using the customized
tissue probability maps into gray matter, white matter, and CSF,
followed by the hidden Markov random field clean-up step. All
images were modulated, and smoothed with a 12-mm full-width at
half maximum smoothing kernel.
Total brain tissue volumes, normalized for subject head size,
were calculated from the high-resolution T1-weighted images,
using the well-established cross-sectional version of the Structural
Imaging Evaluation of Normalized Atrophy (SIENA) software
(SIENAx) [13].
Statistical Analysis
Data were testes for normal distribution with the Wilk-Shapiro
test. Changes of ALSFRS, JTT and cognitive performance from
baseline to Day 30 and 100 were examined between groups using
a two sample t-test. Fisher’s Exact Test was used to assess
differences in the number of AEs between groups. Differences in
laboratory parameters and vital signs were assessed with a two
sample t-test.
Single neurocognitive test results were Z-transformed with a
mean score of 0 and standard deviation of 1; mean Z-scores of
cognitive domains were then calculated by taking the mean of the
individual Z-scores. For timed tests, the sign of the Z-score was
reversed so that improved performance resulted in a higher score
in all tests. Differences in neurocognitive test results between
groups were assessed with either two sample t- test or Mann-
Whitney U test as appropriate. All data are given as means 6 SD,
unless stated otherwise. A two-tailed P value ,0.05 was
considered significant. All statistical analyses were performed
using SPSS 16.
Voxel-wise statistical tests were performed on FA and gray
matter values using Factorial ANOVA in SPM5 (http://www.fil.
ion.ucl.ac.uk/spm/). We hypothesized that all ALS patients (at
Visit 1) would show damage to white matter tracts reflected as
decreased FA when compared to the 32 controls. This hypothesis
was tested using cross-sectional comparisons, i.e. two-sample t-tests
performed on Visit 1 data (pre-medication). Differences between
Table 1. Patient demographics and clinical characteristics at
baseline.
Parameter G-CSF Placebo
Age [years] 51.8610.1 50.0612.2
Gender (male/female) 1/4 3/2
Month since diagnosed 13.968.1 12.566.9
Duration of symptoms [month] 19.568.4 19.167.5
Years of education 11.963.1 12.162.3
ALSFRS at baseline 27.462.5 29.364.6
Total time for JTT at baseline
[seconds]
52.4611.3 54.668.1
Riluzole treatment since [month] 12.465.4 11.963.2
Onset of ALS-Symptoms Bulbar: 0
Lower limb: 2
Upper limb: 3
Bulbar: 1
Lower limb: 2
Upper limb: 2
Blood pressure (systolic/diastolic)
[mmHg] at baseline
134/79613.5/11.7 137/83614.2/10.7
heart rate [beats/minute] at
baseline
78613.4 73610.9
body temperature [uC] at baseline 35.460.5 35.960.4
Differences were not significant for any parameter (all P’s.0.05); mean 6 SD
given.
doi:10.1371/journal.pone.0017770.t001
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group vs. controls were calculated. Secondly, differences in FA
changes between ALS patients treated with G-CSF and the ALS-
Placebo group in the 100 days following Visit 1 were assessed. This
was tested using a factorial design, with VISIT (Visit 1, Visit 2) as
the first factor, and GROUP (ALS-GCSF, ALS-Placebo), as the
second factor. We hypothesized that there would be an overall
group difference in FA change between these groups, manifesting
as a significant interaction between GROUP and VISIT. Age was
included as covariate because of the known or potential effects on
FA. Additionally, follow-up paired comparisons (t-tests) were used
to investigate within group longitudinal changes in FA values.
VBM data of gray matter were analyzed in accordance to the
analyses of FA-maps: Both cross-sectional comparisons between
ALS patients and controls (two sample t-test) and longitudinal GM
changes within both ALS groups were tested (paired t-test and
Factorial ANOVA with VISIT as the first factor and GROUP as
the second factor).
Differences in total brain volumes between both ALS groups
(GM, WM, relative and normalized brain volumes) and to the
group of healthy controls were assessed by analysis of covariance,
modeling the factor age as co-variable.
Ethics
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. This study was carried out in strict accordance with
the principles expressed in the Declaration of Helsinki. The study
was approved by the local ethics committee of the University of
Mu ¨nster and the German Federal Institute for Drugs and Medical
Products. All participants in this study gave written informed
consent.
Results
Five placebo-treated patients and 4 ALS patients treated with
G-CSF completed the study, including both MRI scans. One
patient died of intracranial hemorrhage due to an accidental fall
shortly after enrolment and randomization, but before being
treated with G-CSF. All individuals who received at least one dose
of study medication tolerated the medication well and were able to
complete the study.
Clinical tests (total time of JTT, ALSFRS scores, and z-scores of
each cognitive domain) did not show a significant difference
between both groups in change from baseline to day 30 and day
Table 2. Neuropsychological test results at baseline.
ALS Controls
Cognitive domain and tests Score (Percentile) Evaluation z-scores Score (Percentile) Evaluation z-scores
Dementia screening 0.005 20.002
MMSE 29.1 normal 28.9 normal
Boston Naming Test 13.9 normal 14.0 normal
Attention and Working memory 20.032 20.022
NAI- Digit Symbol Substitution 31.0 (56.2) normal 33.1 (60.7) normal
- CWIT reading 56.8 (44.2) normal 60.0 (50.4) normal
- CWIT colour naming 54.3 (29.0) close below
average
52.9 (27.9) close below
average
WMS-R - Digit Span Forward 11.7 (51.8) normal 12,6 (54.8) normal
- Digit Span Backward 11.7 (41.6) normal 11.9 (42.0) normal
Trail-making test [A] 45.2 (33.4) close below
average
36.0 (50.1) normal
Executive function 20.001 20.011
CWIT - interference condition 17.7 (50.9) normal 19.8 (52.8) normal
RWT - Letter fluency (‘S’) 16.2 (47.4) normal 16.4 (49.0) normal
Trail-making test [B] 100.1 (49.8) normal 96.0 (53.0) normal
Visuospatial skills 20.081 0.045
ROCF - Copy 20.8 21.6
- Delayed recall 12.4 (38.8) normal 14.2 (42.0) normal
- Difference Copy- Delayed [%] 229.3% 229.9%
Verbal learning and memory 0.027 20.024
AVLT - Recall trial 1 6.8 (50.2) normal 6.8 (51.3) normal
- Recall trial 5 12.2 (51.1) normal 11.5 (30.5) close below
average
- Total trials 1 to 5 48.2 (54.4) normal 45.7 (49.0) normal
- Delayed recall 10.5 (55.8) normal 11.3 (58.4) normal
- Recognition (True Positive – False Positives) 13.9 (59.5) normal 12.8 (52.1) normal
Differenceswerenot significant for any domain (all P’s.0.05). SD = Standard Deviation;NAI = NurembergGerontopsychologicalInventory; CWIT = Color-Word- Interfer-ence
Task; RWT = Regensburg Word Fluency Test; WMS-R = Wechsler Memory Scale-Revised; AVLT = Auditory Verbal Learning Test [German Version]; RCFT = Rey-Osterrieth
Complex Figure; MMSE = Mini-Mental State Examination.
doi:10.1371/journal.pone.0017770.t002
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follow-up dates were completed by the ALS patients.
On cross-sectional comparison, voxel-based analysis revealed a
widespread decline in FA in ALS patients when compared to the
healthy controls (Figure 2, upper row). These symmetrical WM
changes were most prominent in the corticospinal tracts, in
subcortical WM of the precentral gyrus, and its connecting fibres
in the frontocentral parts of the corpus callosum. Anatomic
pattern of FA changes were similar in both ALS groups (at visit 1)
were separately compared to the control group.
On longitudinal analysis, ALS patients treated with placebo
showed greater and more widespread decline in FA from Visit 1 to
Visit 2 (day 100) compared to the ALS patients treated with G-
CSF. As shown in Figure 3 the corticospinal tracts (ranging from
subcortical regions to the brainstem), frontal WM including
connecting fibres of the frontal corpus callosum, and temporal
WM showed significantly lower FA values in the untreated ALS
group. An interaction in the opposite direction (ALS patients
treated with G-CSF showing a greater decline in FA from Visit 1
to Visit 2 compared to ALS-Placebo patients) was also tested. This
analysis yielded small symetrical clusters of decreased FA in
posterior thalamic regions (Figure 3).
Post hoc t-test of SPM-ANOVA indicated that FA decreased
from Visit 1 to Visit 2 mainly bilateral in the subcortical WM of
the precentral gyrus in the ALS-G-CSF group (Figure 2, middle
row). In the ALS-Placebo group, post hoc analysis also indicated
WM changes in these regions. Unlike the G-CSF group the ALS-
Placebo patients additionally showed significant clusters of
decraesed FA over time in several major white matter tracts
including the occipital lobes, frontal regions, and connecting fibres
in the corpus callosum (Figure 2, lower row). Interestingly, the
localization of FA changes was similar to the clusters of decreased
FA in the initial voxel-wise analysis between ALS patients and the
healthy controls (Figure 2, upper row). Thus, in particular white
matter tracts that were initially detected as deficient in our ALS
patients continued to lose fibre integrity over time.
VBM analysis showed no differences in local GM between ALS
patients and controls or between both ALS groups. Additionally,
no longitudinal GM changes within each ALS group were
observed during the study period. There were also no differences
in brain volumes between both ALS groups and to the group of
healthy controls.
Percentage of patients in each group with at least one AE (mild
or moderate in severity) was 75% in the G-CSF, 80% in the
placebo group (not significant); no severe AE that led to
discontinuation of the study was reported. 72% of AEs in the G-
CSF group and 53% in the placebo group were classified as
possibly or probably related to the treatment. This effect was also
not significant (see Table 4 for details). All treatment related events
were within the well-described side effect profile of G-CSF
treatment, most often headache (n=3), bone pain (n=3), and
malaise (n=2).
Leukozyte count revealed a significant difference between
groups for day 2, 4, 6, 8, 10, and 23 and 25 (Figure 4). Highest
leukozyte count, reached in one patient on day 8, was 48,390/ml.
For platelet count, a reversed pattern was noted, with a slight
decrease in the G-CSF group starting on study day 2. However,
the difference did not reach statistical significance at any day of the
study, with a lowest platelet count of 124/nL on day 8. For
erythrocyte count, no significant difference between the study
groups was found. Analysis of blood pressure, heart rate, and body
temperature revealed no significant difference between groups at
any day of the study.
Discussion
The present study demonstrated feasibility of a subcutaneous
treatment of ALS patients with G-CSF over a time course of 25
days, and of the tests and MR measurements conducted. G-CSF
was well tolerated. As expected with the very small number of
patients, no signals of efficacy could be deducted from the clinical
parameters measured (ALSFRS, motor hand functions and
neurocognition). Surprisingly, we did detect signals of efficacy
using MR imaging: We discovered a reduction in structural
disintegration of white matter tracts in ALS patients treated with
G-CSF.
So far, only data from one randomized controlled trial with G-
CSF in ALS patients are available [14]. In accordance to our
findings on imaging, this trial also noted a trend of slowing disease
progression following G-CSF treatment. A few other trials
demonstrated safety of G-CSF application in ALS patients [15–
17]. However, this is the first study using advanced neuroimaging
techniques as a biomarker in an ALS trial. DTI provides non-
invasive information about the integrity of white matter by
quantitative measurement of directionality of axonal fibres [18]. It
Table 3. Primary clinical endpoints during treatment.
ALS Controls
Baseline Day 30 Day 100 Baseline Day 30 Day 100
ALSFRS scores (mean ± SD) 35.4±7.6 34.6±8.5 35.3±9.4 35.8±7.0 34.1±8.9 34.4±8.2
Jebsen Taylor Test [seconds]* (mean ± SD) 49.5±7.1 52.1±9.2. 50.1±6.6 51.7±7.7 54.2±6.2 50.8±8.1
Cognitive domains
# (z-scores)
Dementia screening 0.005 0.010 20.007 20.002 20.024 0.005
Attention and Working memory 20.032 20.008 20.050 20.022 20.046 0.032
Executive function 20.001 20.011 20.052 20.011 0.041 0.013
Visuospatial skills 20.081 0.011 0.023 0.045 20.061 20.038
Verbal learning and memory 0.027 20.007 0.018 20.024 0.019 20.076
Differences between groups were not significant for any of the time-points, nor were improvement from baseline to mean of Day 30 and Day 100.
*Performance in this test was reflected by total time needed to complete the six subtests; Number of errors was likewise comparable between groups (not significant).
#See table 2 for the detailed neuropsychological test batteries of each cognitive domain.
ALSFRS = ALS functional rating scale.
doi:10.1371/journal.pone.0017770.t003
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fractional anisotropy (FA) of patient compared to the healthy controls (ANOVA, p,0.001, uncorrected; 50 contiguous voxels). Statistical FA-maps
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17770Figure 3. Longitudinal interaction between VISIT and GROUP. Placebo-treated ALS patients showed a greater and more widespread decline
in FA over time, compared to ALS patients treated with G-CSF (shown in orange; p,0.005, uncorrected; 50 contiguous voxels). These FA changes
mainly involved the corticospinal tracts, frontal WM including connecting fibres of the frontal corpus callosum, and temporal WM. Anatomical
distribution of decreased FA values in ALS patients treated with G-CSF relative to untreated ALS patients over time are shown in blue (p,0.005,
uncorrected; 50 contiguous voxels). These clusters were much less widespread, mainly encompassing posterior thalamic regions. Slice positions are
indicated in the MNI coordinates.
doi:10.1371/journal.pone.0017770.g003
were superimposed on an averaged FA template of the control group. Colored bars represent t-values; display threshold is set at t value .3.16.
Upper row: Cross-sectional comparison of 10 ALS patients when compared to 32 healthy controls (Visit 1). FA of the ALS patients were significantly
reduced in WM areas covering widespread parts of the brain, most prominent in the corticospinal tracts, in subcortical WM of the precentral gyrus,
and it’s connecting fibres in the corpus callosum. Anatomic pattern of FA changes did not alter significantly when both ALS groups were compared
separately to the control group. Lower and middle row: Clusters of FA decreases from Visit 1 to Visit 2 in ALS patients treated with G-CSF (middle
row) and in the ALS-control group (lower row). ALS patients treated with G-CSF showed small regions of decreased FA, mainly affecting bilateral
subcortical WM of the precentral gyrus, whereas the placebo group showed a greater and more widespread decline in FA during the study period.
The localization was similar to the clusters of decreased FA in the initial voxel-wise analysis (upper row). Hence, white matter tracts that were initially
detected as deficient continued to lose fibre integrity over time.
doi:10.1371/journal.pone.0017770.g002
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associated with disintegration of WM and, thus, has great diagnostic
promise for ALS. Changes in FA have functional relevance since
they are correlated to clinical symptoms and histopathological
changesinearlystagesofneurodegenerativediseases[19].Thus,the
slowing of the localized FA decrease that was found in the present
study is most likely the structural correlate of a subclinical benefit of
G-CSF. This finding is backed by recent studies revealing that DTI
has the greatest diagnostic potential for ALS, and has a proven
sensitivity to progression of the disease [20–22]. Furthermore, in a
study of presymptomatic individuals with familial ALS, FA changes
were the earliest detectable changes [23]. DTI changes also showed
a good correlation with physiological indices and clinical severity in
ALS patients [24–26].
The FA changes were most prominent in the corticospinal tracts,
in subcortical WM of the precentral gyrus, and its connecting fibres
in the corpus callosum. This neuroanatomical pattern was in
considerable accordance to former studies using voxel-based DTI
analysis in ALS patients and reflects the presence of microstructural
damage along motor fibres, which was correlated with the degree of
motor disability [21,24,27]. Degeneration of upper motor neurons
usually starts in the primary motor cortex, and secondary
degeneration of motor fibres subsequently occurs along the
corticospinal tract [28]. However, in the current study VBM did
not show significant differences in grey matter between ALS groups
or ALS patients and controls, whereas DTI revealed reproducible
results, even in this small sample of patients. These findings support
former studies concluding that VBM or other volumetric methods
might be rather insensitive to image the subtle primary involvement
of the motor cortex in neurodegenerative disease, and that DTI is
superior to depict an early involvement by imaging the subsequent
degeneration of motor fibres [29–33].
The extra-motor and widespread FA decline in the untreated
patient group during the study period supported the notion, that
ALS is a multisystem disorder. These changes in subcortical
regions beyond the limits of the primary motor areas are well-
known and also clinically relevant [34–37]. Post-mortem studies in
humans have revealed that lower FA in these regions reflects the
extent of astrogliosis and of myelin and, in particular, axonal loss
in the white matter [38]. These structural changes have accounted
for the slower performance on many motor skills and cognitive
tasks [39,40]. Hence, it has been repeatedly shown, that FA is the
most sensitive MR-imaging correlate of executive dysfunction
[41,42], the cognitive domain that is recognized to be particularly
affected in ALS patients [43,44]. Due to the small number of
patients, we could not show such correlations. However, although
the clinical symptoms that are associated with these FA alterations
might be limited, they could have a relevant impact on overall
daily function [45–48].
In previous experimental studies, G-CSF was shown to protect
cultured motoneurons from apoptosis, led to a significant
improvement in motor performance, and prolonged overall
survival of ALS-mice [5,6,49]. Motoneurons in the spinal cord
strongly expressed the receptor for G-CSF, and transgenic
overexpression of G-CSF in the CNS improved outcome [50].
Parallel to its functions following cerebral ischemia, G-CSF may
act as endogenous neuroprotective factor on motoneurons in
neurodegenerative diseases. Thus, G-CSF may have a potential as
disease-modifying drug in ALS. Furthermore, recent studies have
revealed that G-CSF increases microglial recruitment in ALS
model mice and restored microglial responses and function [51].
Since inflammation, including microglial dysfunction and T cell
infiltration of white matter, is a neuropathological hallmark of
ALS [52], G-CSF might also directly improve structural integrity
of fiber tracts yia these effects.
The commonly used ALSFRS score is a rather insensitive, non-
parametric tool to measure activities of daily living in ALS patients,
which could explain some of the negative results [31]. Although in
this study the clinical tests were extended by the JTT and a
neuropsychological test battery, we also failed to demonstrate a
significant clinical benefit of G-CFS treatment, which is due to the
small sample size. In recent studies, ALS patients were recruited
based on the revised El Escorial criteria resulting in a patient
population at an already progressed and relatively late phase of the
disease, possibly beyond the therapeutic window. At least 30% of
anterior horn neurons are degenerated when patients are recruited
at this time of the disease [28]. Establishing an effective treatment at
this stage of the disease appears to be very difficult, and indeed
recent ALS trials were all negative. Our data demonstrate for the
first time widespread and progressive microstructural damage of
white matter tracts assessed by FA analysis that can be modulated
by drug treatment. Thus, a more intensive training regime in earlier
phases of the disease as done here, combined with a drug treatment
might be more promising to achieve clinically significant effects in
neurodegenerative diseases such as ALS. Future studies should
consider a recruitment of patients in earlier stages (probable ALS
and probable laboratory supported ALS) in addition to higher doses
or longer application of G-CSF, because both experimental and
clinical data suggest higher doses of G-CSF to be associated with
better functional neurological outcome [5,6,53]. For this purpose,
sensitive biomarkers in addition to an early therapeutic approach
might be necessary. FA analysis of white matter is sensitive to early
Table 4. All adverse events (AEs) and treatment-related AEs, listed by system organ class.
Side effects All Adverse Events Treatment-related AEs (probable or possible)
Placebo G-CSF Placebo G-CSF
General disorders and administration site conditions 32 1 2
Nervous system disorders 54 2 2
Musculoskeletal and connective tissue disorders 53 4 2
Infections 10 0 0
Skin and subcutaneous tissue disorders 01 0 1
Investigations 11 1 1
(n=11 in the G-CSF group, n=15 in the placebo group).
Incidences of events were not significantly different between both groups (Fisher’s Exact Test; all P’s.0.05).
doi:10.1371/journal.pone.0017770.t004
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PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17770therapeutic effects, even in a small sample of patients, and thus may
represent such an effective marker for therapeutic monitoring in
ALS [54].
In conclusion, our results are paving the way for properly
powered trials with optimized regimes and escalated G-CSF
dosages, combined with voxel-wise DTI analysis as a sensitive tool
to quantify subtle brain tissue alterations.
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